Blarcamesine hydrochloride 是一个 Sigma-1 受体激动剂，其 IC₅₀ 值为 860 nM。

Blarcamesine hydrochloride is a Sigma-1 Receptor agonist with an IC 50 of 860 nM.

Solid

IC50: 860 nM (Sigma-1 Receptor)

The pre-administration of Blarcamesine leads to a dose-dependent attenuation of the scopolamine induced alternation deficit, significant at 1 and 3 mg/kg. The pre-treatment with Blarcamesine hydrochloride attenuates the impairments of step-through latency, dose dependently and significantly at doses higher than 0.3 mg/kg. The Blarcamesine hydrochloride treatment dose-dependently blocks the recognition memory deficit, with a significant effect measured at 1?mg/kg. One day after injections, the significant Aβ 25-35 -induced decrease in Akt phosphorylation is significantly attenuated by Blarcamesine hydrochloride at 0.1 and 1?mg/kg dose. Seven days after injections, Blarcamesine hydrochloride attenuates the decrease in Ser phosphorylation induced by the peptide at 0.3 and 1?mg/kg. The Blarcamesine hydrochloride treatment dose-dependently prevents the Aβ 25-35 -i

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

[1]. Villard V, et al. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011 Aug;25(8):1101-17.
[2]. Valentine Lahmy, et al. Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic andσ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimers Disease. Neuropsychopharmacology

In Vitro: H₂O : 100 mg/mL (314.61 mM; Need ultrasonic)DMSO : 25 mg/mL (78.65 mM; Need ultrasonic)配制储备液